SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for alleged securities fraud. The lawsuit claims ARS made false and misleading statements regarding the timeline for insurance coverage of its drug neffy, which impacted its commercialization and led to investor damages. Shareholders who purchased SPRY shares between March 9, 2026, and June 24, 2026, are encouraged to contact SBS before the October 5, 2026 deadline to potentially serve as lead plaintiff.
Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Urged to Join Class Action Before October 5, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud between March 9, 2026, and June 24, 2026. The lawsuit claims that the company made misleading statements regarding expanded insurance coverage for its product, neffy, through CVS Caremark. Investors are urged to join the class action before October 5, 2026, to explore potential recovery.
ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026, of the October 5, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expanded insurance coverage timeline for its epinephrine nasal spray, neffy, with CVS Caremark, causing investors to purchase shares at inflated prices. Investors are encouraged to contact the firm to join the class action.
ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire,
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against ARS Pharmaceuticals (NASDAQ:SPRY) for investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals failed to disclose risks regarding the expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors have until October 5, 2026, to apply to be appointed as lead plaintiff.
Shareholders of ARS Pharmaceuticals, Inc. (SPRY): Protect Your Rights Before October 5, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud between March 9, 2026, and June 24, 2026. The lawsuit claims that ARS Pharmaceuticals made misleading statements regarding expanded insurance coverage for neffy through CVS Caremark, which led to a significant stock price decline when the lack of coverage was revealed. Investors are encouraged to contact the firm to learn about their rights to potentially recover losses before October 5, 2026.
Officer Eric Karas proposes selling 100,000 shares of ARS Pharmaceuticals (SPRY).
Eric Karas, an officer at ARS Pharmaceuticals (SPRY), has proposed selling 100,000 common shares with an approximate sale date of October 1, 2026, valued at $426,096.77. The notice also reveals prior sales by Karas including 100,000 shares sold on September 30, 2026, for $431,560.00 and 14,064 shares sold on September 11, 2026, for $69,761.66. These proposed and past transactions are detailed in a Form 144 SEC filing.
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Faruqi & Faruqi, LLP has issued a shareholder notice reminding ARS Pharmaceuticals investors of the securities class action lawsuit deadline on October 5, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expanded insurance coverage for neffy through CVS Caremark, which led to a significant stock price drop. Investors who suffered losses between March 9, 2026, and June 24, 2026, are encouraged to contact the firm to discuss their legal options and potentially seek the role of lead plaintiff.
Eric Karas proposes selling 100,000 ARS Pharmaceuticals (SPRY) shares after a $69.8K September sale.
Eric Karas, an officer at ARS Pharmaceuticals (SPRY), has proposed selling 100,000 common shares valued at $431,560. This proposed sale stems from a stock option exercise dated September 30, 2026. Karas also reported a previous sale of 14,064 common shares on September 11, 2026, which generated $69,761.66.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for shareholders who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for CVS Caremark formulary coverage of its drug, neffy, leading to a significant stock price drop when the July 1, 2026, coverage date was missed. Investors who suffered losses have until October 5, 2026, to seek appointment as lead plaintiff.
Did You Lose Money on ARS Pharmaceuticals, Inc. (SPRY)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that the company made misleading statements regarding the expanded insurance coverage timeline for its product neffy through CVS Caremark, leading to a significant stock price decline when the lack of coverage was revealed. Investors who suffered losses are urged to contact Levi & Korsinsky before October 5, 2026, to explore potential recovery.
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for expanded insurance coverage of its drug neffy with CVS Caremark. Following the announcement on June 24, 2026, that CVS Caremark had delayed its decision until January 2027, ARS Pharmaceuticals' stock price declined by nearly 24%.
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR
The Rosen Law Firm is reminding investors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) about the October 5, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors who purchased securities during the class period (March 9, 2026, and June 24, 2026) are encouraged to contact the Rosen Law Firm for potential compensation.
Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Contact Levi & Korsinsky Before October 5, 2026 to Join Class Action
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims that ARS Pharmaceuticals made false and misleading statements regarding expanded insurance coverage for neffy through CVS Caremark. Following the announcement that coverage would not be expanded by the expected deadline, the company's stock price dropped significantly.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and its officers, alleging violations of federal securities laws. The lawsuit claims that ARS Pharmaceuticals made misleading statements and concealed material facts regarding the expected timeline for expanded insurance coverage for neffy through CVS Caremark, harming investors who purchased securities between March 9, 2026, and June 24, 2026. Investors are urged to join the class action by October 5, 2026, to potentially recover damages.
Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action
Faruqi & Faruqi, LLP is urging investors of ARS Pharmaceuticals (NASDAQ: SPRY) to seek legal counsel regarding a securities class action lawsuit before the October 5, 2026, lead plaintiff deadline. The lawsuit alleges that ARS Pharmaceuticals and its executives made misleading statements concerning the timeline for expanded insurance coverage of neffy through CVS Caremark, leading to a 24% stock drop on June 25, 2026. Investors who purchased ARS shares between March 9, 2026, and June 24, 2026, are encouraged to contact the firm to discuss their options.
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASD
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that the company's stock fell significantly after it disclosed that no new commercial formulary additions or coverage decisions had been issued for its drug, neffy. Investors are encouraged to join the case by October 5, 2026, to serve as a lead plaintiff.
Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.
Robbins LLP is reminding stockholders of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a securities class action lawsuit filed against the company. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors who purchased SPRY securities between March 9, 2026, and June 24, 2026, and suffered losses, have until October 5, 2026, to seek appointment as lead plaintiff.
Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) Over Securities Violations - Contact Levi & Korsinsky Today
A class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims that the company made misleading statements regarding the timeline for expanded insurance coverage of its product, neffy, through CVS Caremark. Following the announcement that this coverage was delayed, ARS Pharmaceuticals' stock price declined significantly.
Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.
Robbins LLP is reminding investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a pending securities class action lawsuit, with a lead plaintiff deadline of October 5, 2026. The lawsuit alleges that ARS Pharmaceuticals misled investors regarding the expected timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. The company's stock declined significantly after it announced that the expanded coverage would not be in place by the anticipated July 1, 2026, deadline.
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026
Kaplan Fox & Kilsheimer LLP is encouraging investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to contact the firm regarding a class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements to investors, leading to a significant stock drop after announcing no new commercial formulary additions or coverage decisions for its product neffy. Investors who purchased ARS securities between March 9, 2026, and June 24, 2026, have until October 5, 2026, to move the court to serve as a lead plaintiff.
Securities Class Action Lawsuit Filed Against ARS Pharmaceuticals, Inc. (SPRY) - Levi & Korsinsky Represents Shareholders
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims ARS Pharmaceuticals made false and misleading statements regarding the timeline for expanded insurance coverage for neffy through CVS Caremark, leading to a significant stock price drop. Shareholders who purchased ARS Pharmaceuticals securities between March 9, 2026, and June 24, 2026, are encouraged to contact Levi & Korsinsky to explore their potential for recovery.
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt
SueWallSt has filed a securities class action against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for allegedly misrepresenting the effective date of expanded CVS Caremark coverage for neffy. Investors who purchased SPRY stock between March 9, 2026, and June 24, 2026, and suffered losses, may be affected. The lead plaintiff deadline is October 5, 2026, and affected investors are encouraged to contact SueWallSt.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY), alleging that the company made materially false and misleading statements regarding the expected timeline for expanded insurance coverage for its product neffy. The lawsuit covers investors who purchased ARS securities between March 9, 2026, and June 24, 2026, and seeks to recover damages for federal securities law violations. Investors have until October 5, 2026, to request to be appointed as lead plaintiff.
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. Investors have until October 5, 2026, to move the court to serve as a lead plaintiff. The lawsuit stems from a 23.9% drop in ARS stock price after the company announced no new commercial formulary additions or coverage decisions for its product neffy in the July 1, 2026 cycle.
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit stems from a significant stock price drop following ARS's announcement that no new commercial formulary additions or coverage decisions for neffy were issued in the July 1, 2026 cycle. Investors have until October 5, 2026, to move the court to serve as a lead plaintiff.
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit stems from a 23.9% drop in ARS stock after the company announced on June 24, 2026, that no new commercial formulary additions or coverage decisions for its product neffy had been issued for the July 1, 2026 cycle. Investors have until October 5, 2026, to move the court to serve as a lead plaintiff.
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline
Robbins LLP has filed a securities class action against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals misrepresented the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. The stock price declined significantly after the company announced it did not receive the expected coverage by the July 1, 2026 deadline.
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
SueWallSt is alerting investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a pending securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for expanded CVS Caremark insurance coverage for its product, neffy, leading to a significant 23.9% stock price drop. Investors who purchased shares between March 9, 2026, and June 24, 2026, are encouraged to contact SueWallSt to inquire about eligibility to recover losses and potentially seek lead plaintiff status.
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP reminds investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about an upcoming securities class action deadline of October 5, 2026. The lawsuit alleges that ARS Pharmaceuticals overstated its progress in removing prior authorization barriers with CVS Caremark for its drug, neffy, leading to a significant stock price drop when a decision was reserved until January 2027. Investors who purchased shares between March 9, 2026, and June 24, 2026, and suffered losses may be eligible to recover compensation.
LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
The Shareholders Foundation, Inc. has issued a lawsuit alert for investors who lost over $100,000 with ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares purchased between March 9, 2026, and June 24, 2026. A lawsuit was filed alleging that ARS Pharmaceuticals made false or misleading statements regarding potential timeline issues with CVS Caremark’s formulary addition and coverage decision for neffy. Investors with losses are advised to contact the Shareholders Foundation by the deadline of October 5, 2026.
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) and its officers, alleging violations of federal securities laws. The lawsuit claims that ARS Pharmaceuticals made misleading statements and concealed material adverse facts regarding the timeline for expanded insurance coverage for neffy through CVS Caremark. Investors who purchased ARS securities between March 9, 2026, and June 24, 2026, are encouraged to join the case and have until October 5, 2026, to request to be appointed lead plaintiff.
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) and its officers. The lawsuit alleges that the company made misleading statements regarding the expected timeline for expanded insurance coverage for neffy. Investors who purchased ARS securities between March 9, 2026, and June 24, 2026, have until October 5, 2026, to request to be appointed as lead plaintiff.
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Faruqi & Faruqi, LLP is reminding investors of ARS Pharmaceuticals (NASDAQ: SPRY) about an upcoming October 5, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for expanded insurance coverage of its product, neffy, through CVS Caremark, causing its stock price to drop significantly. Investors who purchased ARS Pharmaceuticals securities between March 9, 2026, and June 24, 2026, are encouraged to contact the firm to discuss their legal rights.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026, of the October 5, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expected timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark, causing investors to purchase securities at artificially inflated prices. Investors who bought shares during this period may be entitled to compensation and can join the class action by contacting the firm.
Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action
Faruqi & Faruqi, LLP is urging investors of ARS Pharmaceuticals (NASDAQ: SPRY) who suffered losses to contact them regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made false or misleading statements regarding the timeline for expanded insurance coverage for neffy through CVS Caremark. Investors who purchased shares between March 9, 2026, and June 24, 2026, have until October 5, 2026, to seek the role of lead plaintiff.
Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a class action lawsuit filed against the company. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding payer access for its drug, neffy, between March 9, 2026, and June 24, 2026, leading to a significant stock price drop. Investors who purchased ARS securities during this period and suffered losses are encouraged to join the case, with a lead plaintiff deadline of October 5, 2026.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for alleged securities fraud. The lawsuit claims ARS made false and misleading statements regarding the timeline for insurance coverage of its drug neffy, impacting its commercialization. Investors who purchased SPRY shares between March 9, 2026, and June 24, 2026, are encouraged to contact SBS to discuss lead plaintiff appointments before the October 5, 2026 deadline.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for alleged federal securities law violations. The lawsuit claims ARS Pharmaceuticals made misleading statements and concealed adverse facts regarding the expected timeline for expanded insurance coverage for their product, neffy. Investors who suffered losses are encouraged to join the case and have until October 5, 2026, to request lead plaintiff appointment.
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact Levi & Korsinsky
A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) due to alleged misrepresentations regarding CVS Caremark's coverage for neffy. The lawsuit claims the company misled investors about the effective date of expanded coverage, causing a significant stock drop. Investors who purchased SPRY stock between March 9, 2026, and June 24, 2026, may be affected, with a lead plaintiff deadline set for October 5, 2026.
Important Notice to Long-Term Shareholders of ARS
Grabar Law Office is investigating potential breaches of fiduciary duties and securities fraud claims on behalf of long-term shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), Roblox Corporation (NYSE: RBLX), Symbotic Inc. (NASDAQ: SYM), and The Simply Good Foods Company (NASDAQ: SMPL). Shareholders who purchased shares before specified dates and still hold them are encouraged to contact the law office to learn about seeking corporate reforms and other remedies.
Important Notice to Long-Term Shareholders of ARS
Grabar Law Office is investigating potential breaches of fiduciary duty and securities fraud claims against ARS Pharmaceuticals, Roblox Corporation, Symbotic Inc., and The Simply Good Foods Company. Shareholders who held shares of these companies prior to specific dates are encouraged to contact the law office to seek corporate reforms and other remedies. The allegations involve issues such as misleading statements about product coverage, earnings growth, deployment acceleration, and acquisition integration challenges.
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) and certain officers, alleging federal securities law violations. The lawsuit claims that ARS Pharmaceuticals made materially false and misleading statements regarding the expected timeline for neffy's expanded insurance coverage through CVS Caremark. Investors who purchased ARS securities between March 9, 2026, and June 24, 2026, are encouraged to join the lawsuit, with an October 5, 2026, deadline to request appointment as lead plaintiff.
Securities Fraud Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) - Levi & Korsinsky Reminds Investors of October 5, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expanded insurance coverage for neffy through CVS Caremark. Following the announcement that expanded coverage would not be available by the July 1, 2026 deadline, the company's stock price dropped over 23.9% in one day.
ARS Pharmaceuticals, Inc. (SPRY) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 5, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expanded insurance coverage for neffy through CVS Caremark. The company's stock price declined by over 23.9% after announcing that the expanded coverage would not be in place by the guided July 1, 2026 deadline.
SPRY Investors Have Rights – If You Lost Money Investing in ARS Pharmaceuticals Inc. Contact Robbins LLP for Information Recovering Your Losses
Robbins LLP is reminding investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) that a securities class action lawsuit has been filed on behalf of those who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals misled investors regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. The stock declined significantly after the company announced it did not receive the anticipated coverage by the July 1, 2026 deadline.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP ("SBS") has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for alleged securities fraud. Investors who purchased SPRY shares between March 9, 2026, and June 24, 2026, are encouraged to contact SBS by October 5, 2026, to discuss potentially leading the lawsuit. The complaint alleges that ARS made misleading statements regarding the timeline for insurance coverage of its drug neffy, causing investor damages.
Tejara Capital Ltd Invests $4.86 Million in ARS Pharmaceuticals, Inc. $SPRY
Tejara Capital Ltd has acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) valued at $4.86 million, representing 0.61% of the company. Despite institutional investors owning 68.16% of the stock and a "Moderate Buy" consensus from analysts with a target price of $28.20, ARS Pharmaceuticals faces challenges. The company reported wider-than-expected losses and is dealing with a securities class-action lawsuit concerning potential delays in coverage for its product neffy, alongside recent insider selling.
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit stems from a significant drop in ARS stock price after the company announced no new commercial formulary additions or coverage decisions for neffy by July 1, 2026. Investors are encouraged to contact Kaplan Fox before the October 5, 2026 deadline to potentially serve as lead plaintiff.
ARS Pharmaceuticals (SPRY) insider plans sale after Aug. 18–19 stock disposals
Sarina Tanimoto, an insider at ARS Pharmaceuticals (SPRY), has filed a Form 144 indicating an intended sale of 25,000 shares of common stock, valued at $147,970.00, on August 20, 2026. This planned sale is connected to a stock option exercise for cash. The filing also reports that Tanimoto previously sold 25,000 shares on August 19, 2026, and 49,401 shares on August 18, 2026.
ARS Pharmaceuticals (NASDAQ: SPRY) holder plans 25K-share sale after 100K sold
Richard Lowenthal, a holder of ARS Pharmaceuticals (NASDAQ: SPRY) common stock, intends to sell 25,000 shares on August 20, 2026, through Morgan Stanley Smith Barney LLC after exercising a stock option, with an aggregate market value of $148,160.00. This planned sale follows two previous sales by Lowenthal within the last three months, totaling 100,000 shares sold on August 18 and 19, 2026, for over $638,000. The transaction was disclosed in an SEC Form 144 filing, outlining details about the sale and Lowenthal's relationship to the issuer as an officer, director, and 10% stockholder.
